Verition Fund Management LLC Sells 125,759 Shares of Celcuity Inc. (NASDAQ:CELC)

Verition Fund Management LLC lessened its holdings in Celcuity Inc. (NASDAQ:CELC) by 75.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,916 shares of the company’s stock after selling 125,759 shares during the period. Verition Fund Management LLC’s holdings in Celcuity were worth $595,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in CELC. nVerses Capital LLC acquired a new position in shares of Celcuity in the third quarter valued at $33,000. Prospera Private Wealth LLC bought a new stake in shares of Celcuity during the 3rd quarter worth about $35,000. Values First Advisors Inc. acquired a new position in Celcuity in the 3rd quarter valued at about $86,000. Quest Partners LLC raised its holdings in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after acquiring an additional 1,379 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Celcuity during the third quarter worth approximately $119,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CELC. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th. Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Lifesci Capital assumed coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.17.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $12.73 on Wednesday. The business has a fifty day moving average price of $14.47 and a two-hundred day moving average price of $15.54. The stock has a market capitalization of $472.66 million, a PE ratio of -4.88 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity Inc. has a fifty-two week low of $11.51 and a fifty-two week high of $22.19.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.